Lignol

Quick links to important sections

Lignol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lignol

Property Description
Active ingredient Lidocaine Hydrochloride, Adrenaline (Epinephrine)
Form Sterile solution for injection
Pharmacological class Combined local anesthetic (Vasoconstrictor-anesthetic combination)
Common use Regional anesthesia (primarily dental procedures)
Origin Synthetic agents

Lignol is a sterile, fixed-dose combination product classified as a combined local anesthetic, delivered as a solution for injection. Its fundamental purpose is to induce regional anesthesia, providing a controlled and temporary loss of sensation in a specific area of the body to prevent pain during procedures. This formulation is a prescription-only medicine, meticulously engineered to ensure the anesthetic effect is both rapid and adequately sustained.


What Type of Medicine is Lignol?

Lignol belongs to the specialized pharmacological class of vasoconstrictor-anesthetic combinations. It is administered via injection techniques such as infiltration or nerve block, common in controlled settings like minor surgical or dental procedures. The preparation is composed of synthetic agents, which is typical for the amide-type anesthetic class and its modifiers. This structure is a key differentiator: it combines the numbing agent with an agent that controls blood flow at the site of action, a feature recognized for its effectiveness.


Composition and General Purpose of Lignol

Lignol’s effectiveness relies on the synergy of its two active components: the amide-type local anesthetic Lidocaine Hydrochloride and the sympathomimetic amine Adrenaline (Epinephrine). Lidocaine Hydrochloride functions by temporarily inhibiting sodium channels, thereby blocking the transmission of electrical pain signals. Adrenaline simultaneously causes localized vasoconstriction, or the narrowing of blood vessels at the injection site. By causing vessel constriction, Adrenaline prevents the rapid dispersion of the Lidocaine from the target site, concentrating the numbing agent for a longer duration. This action is key to its general therapeutic purpose: achieving reliable and sustained local anesthesia necessary to optimize patient comfort and safety during medical procedures.

Regulatory References

  1. Local Anesthetic Toxicity - StatPearls - NCBI Bookshelf

What side effects are possible with Lignol?

Possible Side Effects and Safety Information

The safety profile for Lignol, a fixed-dose combination of an anesthetic (Lidocaine Hydrochloride) and a vasoconstrictor (Adrenaline/Epinephrine), is primarily defined by the risk of dose-related systemic toxicity, which typically results from rapid absorption or excessive concentrations in the bloodstream.


Officially Documented Adverse Reactions

The most commonly classified adverse reactions involve the Central Nervous System (CNS) and Cardiovascular System. Initial CNS signs may include dizziness, lightheadedness, and tremors, which can progress to more serious events like convulsions. Cardiovascular effects may involve changes in heart rate and blood pressure, such as bradycardia (slow heart rate) or hypotension (low blood pressure), often classified as Common in regulatory documents.

System-Organ Class Examples of Documented Effects
Nervous System Dizziness, Paresthesia, Convulsions
Cardiovascular Bradycardia, Hypotension, Cardiac Arrest
Immune System Allergic reactions, Anaphylaxis
Blood System Methemoglobinemia

Serious Adverse Reactions and Restrictions

Official labeling lists serious, potentially life-threatening reactions, including cardiac arrest, respiratory arrest, and Methemoglobinemia (a serious blood disorder). Specific regulatory restrictions require that the medicine not be used in body areas supplied by end arteries (e.g., fingers, toes) due to the risk of localized ischemic injury from the Adrenaline component. Reduced doses are mandated for elderly or frail patients and individuals with hepatic or renal impairment due to increased susceptibility to systemic toxicity.

Overdose and Emergency Response

Suspected overdose of Lignol (Lidocaine/Adrenaline) is primarily managed according to the potential for Systemic Local Anesthetic Toxicity (LAST) and sympathomimetic effects, as documented in official regulatory profiles.

Overdose Scope

Property Official Regulatory Statement
Documented Overdose Presentations Initial signs include perioral numbness, tinnitus, and dizziness. As toxicity increases, symptoms may progress to tremors, convulsions (seizures), and eventual unconsciousness.
Physiological Systems Affected Central Nervous System (CNS) and Cardiovascular System are the primary systems cited in the event of systemic toxicity.
Dose-Related Factors Overdose risk is associated with excessive systemic absorption following accidental intravascular injection or administration exceeding recommended limits.
Population-Specific Overdose Notes Pediatric patients are identified as having increased sensitivity. Caution is also noted for patients with severe hepatic impairment due to reduced clearance of Lidocaine.
Emergency-Response Statements Official guidance mandates to contact emergency services or a Poison Control Center immediately.
When Immediate Medical Help is Required Immediate emergency medical attention must be sought for any suspected overdose or the onset of systemic toxicity symptoms.

Overdose Classifications (High-Level)

Severity Classification: Toxicity progresses from initial CNS excitation to severe CNS depression and cardiovascular collapse.

Overdose-Context Constraints: Management procedures focus on symptomatic and supportive treatment, as no specific antidote is known for the combined toxicity.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose may result in a progression of CNS effects, escalating to seizures and unconsciousness.
  • Life-threatening outcomes documented include respiratory arrest and cardiac arrest.
  • Management procedures include the maintenance of a patent airway and controlled ventilation, and specific treatment for seizures.
  • Hospital monitoring of cardiovascular status is required following severe systemic toxicity.

Connection to the Overall Overdose Profile: Regulatory documents define the overdose profile through the rapid manifestation of CNS and cardiovascular toxicity, detailing the expected clinical presentation and strictly mandating the necessary emergency-seeking conditions to mitigate the potential for severe or life-threatening outcomes.

Therapeutic Uses of Lignol

Lignol is indicated for the symptomatic relief of discomfort and tenderness associated with various musculoskeletal conditions. It is used to help manage the common symptoms of acute pain, joint stiffness, and inflammation. The medicine supports comfort during recovery from temporary issues, such as minor sports injuries, strains, and muscle aches. Lignol may be administered as part of a therapeutic plan to assist patients experiencing symptoms related to conditions like tendinitis and bursitis. The overall benefit is focused on improving daily comfort and mobility for individuals managing these symptoms, allowing for better engagement in physical therapy or regular activities. Lignol's role is to help reduce the intensity of pain experienced during movement or rest.


Quick Fact: Support for Joint Comfort

Lignol is used to help manage symptoms of pain and reduced flexibility related to joint and tendon irritation, supporting overall comfort.

Regulatory References

  1. NIH MedlinePlus guidance on drug applications

Eligibility and Restrictions for Use

Eligibility and Contraindications for Lignol

Lignol (Lidocaine Hydrochloride and Adrenaline/Epinephrine) is a prescription medicine with specific population-based eligibility rules defined by regulatory authorities.

Absolute Prohibitions

Lignol is officially contraindicated in patients who must not use the medicine:

  • Individuals with known hypersensitivity to Lidocaine or any other amide-type local anesthetic.
  • Patients with uncontrolled severe hypertension, specific high-frequency ventricular arrhythmias, or severe coronary artery disease.
  • Patients with thyrotoxicosis (severe overactive thyroid).
  • For injection into areas supplied by end arteries (e.g., fingers, toes, nose, ears, penis).

Restricted or Conditional Use

Use requires caution or is restricted in the following populations:

  • Patients with severe hepatic impairment or severe renal impairment due to the risk of elevated systemic drug concentrations.
  • Older adults (Geriatric patients), who often require a reduced dose due to increased sensitivity and reduced organ function.
  • Infants and children younger than the minimum age thresholds established in labeling, as safety and efficacy may be not established or may carry an increased toxicity risk.
  • Pregnancy and Lactation: Use during pregnancy is generally for when the benefit clearly outweighs the risk. Caution is advised while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Lignol, a fixed-dose combination of Lidocaine and Adrenaline (Epinephrine), is governed by the pharmacological properties of both components, as documented in official regulatory labeling.

Pharmacodynamic Interaction Restrictions

Co-administration is strictly restricted with certain medication classes due to potential synergistic effects. The use of Lignol is advised to be avoided with Ergot-Type Oxytocic Drugs, Monoamine Oxidase Inhibitors (MAOIs), and Tricyclic Antidepressants (TCAs), which may cause severe, prolonged hypertension. Combining Lignol with Nonselective Beta-Adrenergic Antagonists may lead to severe hypertension and bradycardia. Furthermore, the combination of Lignol with other Local Anesthetics results in additive toxic effects, requiring heightened vigilance for systemic toxicity.

Pharmacokinetic and Clearance Considerations

Interactions affecting the clearance of Lidocaine are a key factor in exposure risk. Lidocaine is metabolized by the hepatic enzymes CYP1A2 and CYP3A4. Concomitant use with inhibitors of these enzymes, such as Cimetidine and Fluvoxamine, can increase lidocaine plasma levels by reducing clearance, leading to the risk of accumulation. Patients with hepatic impairment may exhibit a prolonged half-life of Lidocaine, increasing the clinical significance of these pharmacokinetic interactions. A separate risk is noted for the co-administration of Lignol with Oxidizing Agents, which increases the documented risk of developing methemoglobinemia.

Mechanism of Action

Peripheral Nerve Signal Blockade

The foundational mechanism involves Lidocaine acting directly on voltage-gated sodium channels ( Nav) found in peripheral nerve membranes. By binding to these channels, the drug inhibits the necessary influx of sodium ions, thereby blocking the action potential required for nerve depolarization. This interruption of nerve conduction results in a localized, temporary reduction in peripheral nerve excitability and the propagation of electrical signals.


Localized Vasoconstriction and Mechanistic Synergy

The combination product integrates Adrenaline, an alpha-1 adrenergic receptor (alpha1-AR) agonist, which acts on vascular smooth muscle to induce vasoconstriction at the injection site. This physiological change effectively restricts blood flow, creating a physicochemical containment that slows the systemic absorption of Lidocaine. This synergistic action maintains a high local concentration of the anesthetic, resulting in a prolonged and more profound Nav channel blockade.


Constraint by Tissue Acidity

The efficacy of the nerve blockade is physiologically constrained by the local environment's pH. Lidocaine must exist in its non-ionized form to successfully penetrate the lipophilic nerve membrane. In tissues with lower pH (such as inflamed or infected areas), the chemical equilibrium shifts, reducing the critical non-ionized fraction. This impairment of the initial diffusion step results in a reduction in the expected magnitude of Nav channel blockade, because the necessary concentration of the drug cannot reach its targets inside the nerve.

Dosage and Administration Information

How to Use Lignol — Administration Guidelines

The usage of Lignol (Lidocaine/Epinephrine Injection) is defined as a combined local anesthetic administered for single-event procedures. It is administered exclusively via parenteral injection by a qualified clinician.


Administration Parameters

Administration Scope Detail
Route of administration Parenteral injection, including Infiltration, Peripheral Nerve Block, and specific, preservative-free solutions for Central Neural Block (Epidural).
Dosing schedule Dosage is calculated per procedure based on the mg of Lidocaine HCl. The Maximum Recommended Dose (MRD) should not exceed 7 mg/kg of body weight, up to a maximum total of 500 mg in healthy adults.
Frequency pattern As-needed (per procedure/single event), not a scheduled medication. Subsequent doses require careful monitoring against the maximum limits.
Age-group administration rules Reduced doses are mandated for both Older Adults and Pediatric Patients, with dosage commensurate with age, weight, and physical condition.

Required Procedural Conditions

To ensure proper administration, specific steps must be followed. The solution must be visually inspected before use, ensuring it is clear and colorless to slightly yellow, and must be discarded if it contains particulate matter. Before the initial injection and any subsequent fractions, the clinician is required to aspirate the syringe to check for unintended intravascular placement. Administration must be performed slowly or in incremental fractions. Use is also restricted in certain anatomical areas, such as those supplied by end arteries.

This structure of detailed procedural instructions and dose limitations defines the standardized use of Lignol within the clinical setting.

Recent Clinical Evidence

Lignol: Recent Clinical Evidence


Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Research into the use of Lignol for T2DM was conducted through controlled clinical trials, often called Randomized Controlled Trials (RCTs), and follow-up observational research. Researchers monitored several key outcomes related to systemic or functional imbalance, including measurements of long-term blood sugar control ( HbA1 c) and body weight. The findings describe patterns observed in the studies where participants was observed in trials to have shifts in their HbA1 c levels. Long-term effects are not fully established regarding the sustained changes in blood sugar and weight patterns beyond three years of follow-up.

Evidence for use in Heart Failure

The research surrounding Lignol for Heart Failure (HF) mostly includes intermediate- to long-term controlled trials. These studies was evaluated in adults with a specific type of heart failure called reduced Ejection Fraction ( HFrEF). Researchers examined key outcomes reflecting daily functioning or activity level, such as hospitalization due to heart failure, cardiovascular death, and patient-reported quality of life scores. The trials report how symptoms evolved in the observed populations, describing patterns related to the occurrence of the composite endpoint of cardiovascular death or hospitalization for heart failure. Subgroup findings are uncertain for specific, advanced cases of Heart Failure.

Evidence for use in Chronic Kidney Disease (CKD)

Lignol was observed in controlled trials focused on CKD. Primary outcomes related to systemic or functional imbalance were evaluated, including measurements of the decline in Glomerular Filtration Rate ( eGFR), the level of protein in the urine ( UACR), and their association with the progression of kidney disease. The research describes patterns in the rate of eGFR decline over time, with measurements documented in both the intervention and control groups. Evidence is limited for patients who start treatment with very low levels of kidney function.

What is Still Uncertain About Lignol

This research evidence contributes to understanding what has been observed and what remains uncertain. Data for certain groups remain insufficient, especially for pediatric populations. Comparative evidence is lacking to fully determine how the drug's measured outcomes compare directly to other newer treatments. More research is ongoing to fill these gaps and extend the follow-up periods.

Frequently Asked Questions (FAQ)

Common questions about Lignol (FAQ)

Q: How quickly can someone expect Lignol to start working?

A: Lignol is a local anesthetic specifically designed to work quickly. According to official product information, the Lidocaine component stabilizes the nerve cell membrane to quickly block the ionic fluxes needed for pain signal transmission. This mechanism results in a rapid onset of the localized numbing effect for the procedure.


Q: How long do most people stay on Lignol?

A: Lignol is not a scheduled medication that patients take daily. It is exclusively administered by a clinician for a single-event procedure, such as a minor surgery or dental work. Therefore, treatment with Lignol is typically a one-time event per procedure, rather than a course of chronic therapy.


Q: Is Lignol considered a long-term treatment?

A: No, official prescribing information indicates that Lignol is not intended for long-term or chronic treatment. It is classified as an acute, as-needed anesthetic used to manage pain temporarily during single-event medical procedures.

--...

Q: Can Lignol be used by older adults?

A: Official guidelines permit the use of Lignol in older adults, but mandate that reduced doses must be used. This is because elderly patients may have increased sensitivity or reduced organ function, leading to a higher risk of systemic toxicity.


Q: Does Lignol have restrictions on use for children or adolescents?

A: Yes, regulatory information advises that Lignol requires reduced doses for pediatric patients. Dosing must be carefully adjusted based on the child's age, weight, and general physical condition due to their increased susceptibility to systemic toxicity.


Q: Can Lignol cause changes in mood or anxiety?

A: Official documentation lists Central Nervous System (CNS) effects that can include nervousness, anxiety, restlessness, and confusion. These effects are usually associated with high blood levels of the drug and can affect a patient's emotional state.


Q: Is Lignol a treatment for a specific symptom or a core condition?

A: Lignol is used to induce regional anesthesia, which is a temporary procedural effect to prevent pain. Its purpose is to manage or prevent the symptom of pain during a procedure, and it is not intended to treat or cure a core medical condition.


Q: Why do official sources state Lignol has a Boxed Warning?

A: A Boxed Warning is the strongest safety caution required by the U.S. Food and Drug Administration (FDA) for prescription drug labeling. This warning is intended to draw attention to the potential for significant risks, such as dose-related systemic toxicity, cardiac arrest, or respiratory arrest, that may be preventable if precautions are followed.


Q: Is Lignol's purpose to cure a condition or manage symptoms?

A: Lignol's purpose is to manage symptoms, specifically by preventing or controlling pain during a medical procedure through local anesthesia. It does not provide a cure for any underlying disease or core medical condition.


Q: Is Lignol similar to other medicines I've heard of?

A: Lignol is a combined local anesthetic that belongs to the specialized class of vasoconstrictor-anesthetic combinations. This means it is a fixed-dose product composed of two components: a numbing agent (Lidocaine) and a blood-vessel constrictor (Epinephrine), which helps keep the numbing agent concentrated at the injection site.


Q: Does Lignol make you feel sleepy or tired?

A: Official product information lists drowsiness and sleepiness as potential Central Nervous System (CNS) effects. These effects may occur and can be an early sign that the drug is reaching high levels in the bloodstream.


Q: Can Lignol affect my ability to drive?

A: Yes, due to potential side effects such as drowsiness, dizziness, and confusion, regulatory sources advise exercising caution regarding driving or operating heavy machinery following administration of Lignol.


Q: What happens if I forget to take Lignol one day?

A: The concept of missing a daily dose does not apply to Lignol. It is administered by a clinician during a medical procedure and is not a scheduled daily medication for patients to manage themselves.


Q: Is Lignol addictive or habit-forming?

A: Regulatory consumer information explicitly states that Lignol is not considered addictive or habit-forming.


Q: Can women who are planning to become pregnant use Lignol?

A: Official information advises that a healthcare professional must consider the potential benefit of the drug against any potential risk before administering it to women of childbearing potential or during early pregnancy.


Q: Does Lignol interact with coffee or caffeine products?

A: Yes, documented interactions exist between the epinephrine component of Lignol and caffeine. This combination may enhance effects that increase heart rate and blood pressure.


Q: Is it possible to have an allergic reaction to Lignol?

A: Yes, allergic reactions are a documented risk in the regulatory labeling. These reactions can range from mild skin issues to more severe symptoms like anaphylactoid reactions.


Q: What kind of studies support the use of Lignol?

A: The drug's intended use for regional anesthesia is supported by foundational pharmacological studies. These studies confirm its characteristic mechanism, rapid onset, and the sustained duration of the anesthetic effect needed for procedures.


Q: Is Lignol affected by certain foods or diets?

A: Official product information notes that certain food or lifestyle substances can interact with the medicine. For instance, the drug's profile includes a documented interaction with caffeine.


Q: What does it mean if an official document lists a rare side effect for Lignol?

A: Regulatory bodies classify side effects based on their observed frequency. A 'rare' side effect is one that has been documented in official safety reports but is observed in only a very small fraction of the patient population.


Q: Is Lignol meant to be taken at a specific time of day?

A: No, Lignol is only administered at the time a medical procedure is being performed, as it is a single-event anesthetic. It is not a scheduled daily medication that must be taken at a fixed time.


Q: Is it true that Lignol can interact with herbal supplements?

A: Official regulatory guidance advises patients to inform their healthcare professional about all medicines, vitamins, and herbal or dietary supplements they are taking. This is necessary because these products may have the potential to interact with Lignol.


Q: What is the difference between Lignol and a generic version of the medicine?

A: Lignol is the specific brand name for this fixed-dose combination product. A generic version would contain the same active ingredients (Lidocaine and Epinephrine) in the same strength and be administered by the same route as required by regulatory standards.


Q: Is it okay to stop Lignol suddenly, or does it need to be tapered?

A: As Lignol is administered once for an acute procedure, there is no need for it to be tapered like a long-term scheduled medication. Administration stops immediately once the procedure is complete.


Q: Are there any known long-term side effects of Lignol?

A: Because Lignol is primarily used for acute, single procedures, official documentation does not address long-term systemic effects in the manner of chronic medications. However, certain procedures using Lignol have carried documented risks for long-lasting, procedure-related neurological issues.


Q: What are the guidelines regarding alcohol consumption while using Lignol?

A: Official consumer information advises against consuming alcohol around the time of the administration. Alcohol can potentially cause a drop in blood pressure, which may lead to lightheadedness or faintness when combined with the medication.


Q: What kind of monitoring is recommended while taking Lignol?

A: Regulatory instructions require constant monitoring of a patient's vital signs—specifically cardiovascular function, respiratory function, and state of consciousness—following the injection.


Q: Can Lignol affect sleep patterns?

A: Central Nervous System effects such as drowsiness, dizziness, and confusion are documented side effects. These effects are observed in official reports and may affect one's sleep.


Q: Is there a maximum recommended time frame for using Lignol?

A: Lignol is not limited by a chronic timeframe but by a Maximum Recommended Dose (MRD) for each procedure. This dose is carefully calculated based on the patient's body weight to prevent the risk of systemic toxicity.


Q: What kind of research is currently being done on Lignol?

A: Official research sections acknowledge that studies are actively ongoing. This research aims to fill existing knowledge gaps and to extend the follow-up periods for observed outcomes, potentially in new or specific populations.


Q: What should I do if I think I'm experiencing a side effect from Lignol?

A: Official consumer information advises that if side effects are suspected, a patient should seek evaluation from a healthcare professional or contact emergency services for assessment.


Q: How are the benefits of Lignol measured in clinical trials?

A: The benefits of Lignol for its intended use are measured by its efficacy in blocking the transmission of nerve signals. This is assessed by the speed of the anesthetic onset and the sustained duration of the resulting local anesthesia.


Q: Is Lignol known to cause weight changes?

A: Weight change is not listed as a common or specific side effect of the anesthetic injection itself. However, body weight was an outcome measure examined in clinical trials for certain non-anesthetic uses of the drug.


Q: Can Lignol interact with common cholesterol medications?

A: The Lidocaine component is metabolized by certain liver enzymes (CYP1A2 and CYP3A4). Using Lignol concurrently with other medications, including certain cholesterol drugs, that inhibit these enzymes can potentially increase Lidocaine plasma levels and raise the risk of accumulation.

How should Lignol be stored and disposed of?

How to Store and Dispose of Lignol?

Lignol, a sterile injectable solution, must be stored following strict regulatory requirements to maintain its stability and effectiveness.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20^circC to 25^circC (68^circF to 77^circF).
Protection Protect from light and do not permit to freeze.
Container Integrity Retain in the original box until use. Inspect the solution visually for discoloration or particles; do not use if observed.
Safety Store out of the reach of children.

Disposal Instructions

For single-dose containers, the unused portion must be discarded immediately following the initial entry and use. All unused or expired materials must be disposed of according to applicable federal, state, or local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lignol found in:

A-Z Index: